|
Anemia
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
|
Anemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Anemia in FAP-I is associated with inappropriately low serum erythropoietin levels.
|
20979939 |
2010 |
|
Anemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Anemia was significantly more common in the boceprevir groups than in the control group, and erythropoietin was administered in 41 to 46% of boceprevir-treated patients and 21% of controls.
|
21449784 |
2011 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Anemia linked to a relative deficiency of renal erythropoietin production is a significant cause of morbidity and medical expenditures in the developed world.
|
22611156 |
2012 |
|
Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Anemia was the most common side effect (n = 55, 72%) requiring erythropoietin and RBV dose reduction.
|
25152985 |
2015 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Anemia and neutropenia were managed with Erythropoietin and Filgrastim supplementation, respectively.Only six patients discontinued therapy.
|
25469044 |
2014 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Anemia Evaluation and Erythropoietin Dose Requirement Among Hemodialysis Patients: a Multicenter Study.
|
28174354 |
2017 |
|
Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Anemia is an important and common problem associated with chronic kidney disease (CKD), which is caused by erythropoietin deficiency, iron-restricted erythropoiesis, inflammation, hypoxia, vitamin D deficiency, hyperparathyroidism, and obesity.
|
28302014 |
2017 |
|
Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Anemia is common in breast cancer patients and can be treated with blood transfusions or with recombinant erythropoietin (EPO) to stimulate red blood cell production.
|
28418910 |
2017 |
|
Anemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Anemia resulting from the reduced expression of erythropoietin (EPO) is a common complication of patients with chronic kidney diseases (CKD).
|
28625716 |
2017 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Anemia is a common complication of chronic kidney disease and is mainly caused by the inability of injured kidneys to produce adequate amounts of erythropoietin.
|
28651951 |
2017 |
|
Anemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Anemia of critical illness is resistant to exogenous erythropoietin.
|
28716301 |
2017 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Anaemia is the consequence of a decrease in erythropoietin production in fibrotic kidneys.
|
28857467 |
2018 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Anaemia is a very common problem in patients with end-stage kidney disease (ESKD) and the use of erythropoietin-stimulating agents (ESA) has revolutionised its treatment.
|
29178879 |
2017 |
|
Anemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Anemia induced increased human erythropoietin RNA levels in liver but not kidney.
|
2928334 |
1989 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Anemia of chronic kidney disease (CKD) is characterized by a lack of synthesis of erythropoietin leading to reduced red blood cell (RBC) formation and aberrant iron recycling.
|
29659573 |
2018 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Anaemia remains highly prevalent requiring treatment with erythropoietin and transfusions.
|
30290796 |
2018 |
|
Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Anaemia in TREX1 D18N mice is accompanied by increased erythropoietin (Epo), normal hepcidin levels and the TREX1 D18N mice display an inappropriate response to anaemic challenge.
|
30422000 |
2018 |
|
Anemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Anemia was present in adenine-fed mice, while PBI-4050 blunted these effects and led to significantly higher plasma erythropoietin (EPO) levels.
|
31308217 |
2019 |
|
Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Anemia is a well-known complication of advanced CKD and treatment with erythropoietin analogues (epoetin) remains a key component of management.
|
31477257 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
CTD_human |
Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.
|
11245434 |
2001 |
|
Anemia
|
0.500 |
Therapeutic
|
disease |
CTD_human |
Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.
|
11245434 |
2001 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Erythropoietin, in its standard role for the treatment of anemia, is often mechanistically regarded simply as increasing blood oxygen-carrying capacity and hence decreasing tumor hypoxia.
|
12138409 |
2002 |
|
Anemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
EPO, in MPMC transplanted mice, was detected up to 3 weeks (peak at 13 +/- 1 mIU/mL), and anemia of uremic mice was corrected (35.3 +/- 0.9 mIU/mL to 41.9 +/- 1.1 mIU/mL).
|
12753297 |
2003 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Erythropoietin (EPO) is a glycoprotein used for curing human anemia by regulating the differentiation of erythroid progenitors and the production of red blood cells.
|
15672835 |
2004 |